We are live on ! Find out more
ACM

Ayer Capital Management Portfolio holdings

AUM $26.8M
This Fund
S&P 500
This Quarter Est. Return
+22.86%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$18.4M
AUM Growth
+$1.46M
Cap. Flow
+$593K
Cap. Flow %
3.22%
Top 10 Hldgs %
100%
Holding
3
New
1
Increased
–
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
PTCT icon
PTC Therapeutics
PTCT
+$7.24M

Top Sells

Rank Stock Value
1
ARTC
ARTHROCARE CORP
ARTC
+$3.97M
2
CELGZ
Celgene Corporation Contingent Value Rights
CELGZ
+$2.68M

Sector Composition

Rank Sector Weight
1 Healthcare 38.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELGZ
1
DELISTED
Celgene Corporation Contingent Value Rights
CELGZ
$11.2M 61.08%
1,399,919
-347,456
-20% -$2.68M
PTCT icon
2
PTC Therapeutics
PTCT
$5.68B
$7.15M 38.92%
+416,666
New +$7.24M
ARTC
3
DELISTED
ARTHROCARE CORP
ARTC
– –
-115,009
Closed -$3.97M

Similar funds

OHCM
Orchard Hill Capital Management New York $22.6M AUM 3.52% 1-Year Est. Return
AC
Altus Capital Mayfield Heights, Ohio $22.6M AUM 34.75% 1-Year Est. Return
IT
Investors Trust Dallas, Texas $32M AUM 1.92% 1-Year Est. Return
WA
Whippoorwill Associates White Plains, New York $19.3M AUM 10.09% 1-Year Est. Return
MCM
Martin Capital Management Elkhart, Indiana $36.5M AUM 4.02% 1-Year Est. Return
ADICC
Abu Dhabi Investment Council Co Abu Dhabi, United Arab Emirates $16.7M AUM 8.06% 1-Year Est. Return
SC
Sumit Capital New York $16.6M AUM 9.66% 1-Year Est. Return
3NC
300 North Capital Pasadena, California $16.3M AUM 27.56% 1-Year Est. Return

Ayer Capital Management's Q3 2013 Portfolio in Review

As of Q3 2013, Ayer Capital Management held 3 positions worth $18.4M, up 8.6% from $16.9M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Ayer Capital Management deployed $593K of net new capital in Q3 2013, opening 1 new position. Its largest new stake was PTC Therapeutics: 416,666 shares worth $7.15M.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets.

On the sell side, the largest reduction was Celgene Corporation Contingent Value Rights, an estimated $2.68M trimmed.

  • Ayer Capital Management's largest Q3 2013 buy was PTC Therapeutics: 416,666 shares worth $7.15M.
  • Ayer Capital Management's biggest Q3 2013 reduction was Celgene Corporation Contingent Value Rights, cutting an estimated $2.68M.
  • Ayer Capital Management fully exited ARTHROCARE CORP in Q3 2013, selling an estimated $3.97M.
  • Ayer Capital Management's ten largest holdings make up 100% of its $18.4M portfolio in Q3 2013.
  • Ayer Capital Management opened 1 new position and closed 1 in Q3 2013.
  • Ayer Capital Management's portfolio value rose 8.6% quarter-over-quarter to $18.4M.

Based on Ayer Capital Management's 13F filing for Q3 2013, filed 14 Nov 2013.